Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis. We hypothesized that inhibition of VEGFR and FGFR by brivanib would inhibit liver fibrosis....
Main Authors: | Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3977817?pdf=render |
Similar Items
-
Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling.
by: Ikuo Nakamura, et al.
Published: (2015-01-01) -
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
by: Ballas MS, et al.
Published: (2011-05-01) -
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab
by: Madsen Christine, et al.
Published: (2012-09-01) -
Brivanib治疗肝癌的临床研究进展
by: QI Xingshun
Published: (2014-04-01) -
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
by: Kayoko Hosaka, et al.
Published: (2020-07-01)